｜Edited by the Peptide Biotech Content TeamRecently, HC0301 project (hereinafter referred to as: HC0301), a Class 1.1 nucleic acid innovative drug independently developed by Zhejiang Haichang Biotech Co., Ltd., has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the indication of advanced hepatocellular carcinoma.
The approval of this ODD represents another significant milestone in the development of Haichang Biotech's nucleic acid innovative drug pipeline, indicating the project's substantial potential in the field of liver cancer. Haichang Biotech will accelerate the progress of clinical trials and market registration for HC0301.
About Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the fourth leading cause of cancer-related deaths. According to the World Health Organization, China is one of the countries with a high incidence of HCC, posing a significant public health challenge.The main risk factors for HCC are chronic hepatitis and cirrhosis caused by any etiology. Chronic hepatitis can result from viral infections (hepatitis B virus and hepatitis C virus), excessive alcohol consumption,Nonalcoholic Steatohepatitis, chronic toxin exposure (such as aflatoxins), etc. Despite advances in antiviral treatments for alleviating hepatitis B and C-related cirrhosis, the incidence of HCC continues to rise due to long-term alcohol consumption, poor dietary habits, and sedentary lifestyles.
HC0301 is an innovative AKT-1 formed by encapsulating Archexin with Haichang Biotech's QTsome™ nucleic acid delivery technology.Antisense OligonucleotideLipid nanoparticle suspension. Currently, a Phase I dose-escalation clinical trial for advanced solid tumors is being conducted in the United States (NCT05267899), which is nearing completion and has demonstrated very good safety and efficacy. Based on a series of preclinical studies and preliminary clinical research data, HC0301 is expected to become a new treatment strategy for advanced HCC, benefiting more patients.
Challenges and Hope in the Treatment of Advanced Hepatocellular CarcinomaHCC has multiple treatment options, including hepatectomy, liver transplantation, ablation therapy, and liverArterial EmbolismChemotherapy, radiotherapy, systemic treatment, etc. The key to treatment selection is individualized decision-making based on the patient's overall condition, liver function, and tumor characteristics. Due to the insidious onset of HCC, most patients are diagnosed at an advanced stage. Systemic treatment can control disease progression, prolong survival time, and improve the quality of life, playing a crucial role in the treatment process of advanced HCC.About U.S. FDA Orphan DrugOrphan Drug Designation (ODD) is a qualification granted by the FDA's Office of Orphan Products Development (OOPD) to drugs (including biologics) that meet the criteria for prevention, treatment, and diagnosis of rare diseases, aiming to encourage the research, development, and production of treatments for rare conditions.Haichang Biotech, located in Hangzhou Medicinal Port, is a national high-tech enterprise focusing on the development of innovative biopharmaceutical technologies, with independent innovation capabilities and global intellectual property rights. The company adheres to its core values of "sharing, progress, truth-seeking, and pragmatism," centering on the development and industrialization of drug delivery systems. It specializes in the development of nucleic acid innovative drugs such as mRNA vaccines and small nucleic acid drugs, as well as advanced complex injectables. Its product pipeline covers areas including infectious disease prevention, tumor immunotherapy, anti-tumor treatments, and pain management.1.Haichang Biotech -- Haichang Biotech | Haichang Biotech | Biopharmaceutical Technology | Pharmaceutical Technology Co., Ltd. (zhejianghaichang.com)2. Haichang Biotech Official Account
